Leadership, Planning and Evaluation

领导、规划和评估

基本信息

批准号：
10627035
负责人：
ROBERT S. MANNEL
金额：
$ 18.86万
依托单位：
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-01 至 2028-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10627035
关键词：
Address Appointment Basic Science Cancer Center Cancer Center Support Grant Catchment Area Clinical Clinical Cancer Center Clinical Research Collaborations Communication Communities Community Outreach Component of the Center for Cancer Research Data Decision Making Development Diabetes Mellitus Doctor of Philosophy Education Effectiveness Ensure Evaluation Evaluation Research Faculty Fostering Funding Geroscience Goals Leadership Malignant Neoplasms Mentorship Minority Groups Minority Women Mission NCI Center for Cancer Research Oklahoma Outcome Persons Play Policies Positioning Attribute Process Productivity Publications Reporting Research Research Activity Resource Allocation Resource Sharing Role Science Strategic Planning Students Training Translational Research Translations Underrepresented Minority Update cancer research center director cancer risk career community engagement community setting design equity, diversity, and inclusion experience improved outcome meetings operation programs

项目摘要

LEADERSHIP, PLANNING AND EVALUATION: ABSTRACT The Stephenson Cancer Center (SCC) conducts formal planning and evaluation activities, under the oversight of the SCC director and senior leadership team, to advance its mission of eliminating cancer in Oklahoma (SCC catchment area) and beyond. Planning and evaluation are critically important for a matrix cancer center like the SCC to ensure optimal coordination, integration, and effectiveness of SCC activities and resource allocation. The following core strategic priorities inform the goals, tactics, and metrics for all SCC research components: 1) enhancing breadth, depth, and impact of cancer-focused research; 2) fostering the translation of discoveries into the clinical or community setting; 3) designing and conducting hypothesis-driven trials to improve outcomes for people with or at risk for cancer; 4) promoting intra- and inter-programmatic collaboration and transdisciplinary team science; 5) enhancing COE to address priority cancers and cancer problems prevalent in the SCC catchment area; 6) increasing training and mentorship opportunities for students and faculty; and 7) enhancing the presence of underrepresented minority persons and women among SCC leadership and membership, and in pipeline programs. For oversight, planning, and evaluation of research activities, SCC Director Robert Mannel, MD has assembled an experienced senior leadership team of associate directors (ADs) who oversee the following functions: basic research (Danny Dhanasekaran, PhD); translational research (Priyabrata Mukherjee, PhD); clinical research (Kathleen Moore, MD); community outreach and engagement (Mark Doescher, MD); education, training, and career enhancement (Rajagopal Ramesh, PhD); diversity, equity, and inclusion (Joan Walker, MD); and research administration (Wade Williams, PhD). Since Mannel’s appointment as SCC director in 2006, strategic planning and evaluation has played a central role in the development of the SCC. The standing Research Leadership Committee (RLC) and Research Steering Committee (RSC), which are comprised of leaders for all research components at the SCC, provide regular forums for planning and evaluating progress. In addition, research leadership is well represented in SCC clinical planning and evaluation. External input from scientific and community advisory boards augment these planning and evaluation activities. New strategic initiatives emerging from planning discussions during the reporting period include: research program realignment (2018); strategic partnerships with the Oklahoma Center for Geroscience (2018) and Harold Hamm Diabetes Center (2019); new initiatives to enhance SCC research focused on catchment area priority cancers and prevalent cancer problems (2019); increased engagement with OU Norman to foster cancer-focused research and collaborations (2020); establishing a new AD position for diversity, equity, and inclusion, and broad planning for how to enhance DEI among SCC leadership and membership, and in pipeline education programs (2021).

领导力、规划和评估：摘要史蒂芬森癌症中心 (SCC) 在监督下开展正式的规划和评估活动 SCC 主任和高级领导团队的成员，推进其在俄克拉荷马州消除癌症的使命（SCC 集水区）及其他区域的规划和评估对于矩阵癌症中心至关重要。与 SCC 一样，确保 SCC 活动和资源的最佳协调、整合和有效性以下核心战略优先事项告知所有 SCC 研究的目标、策略和指标。组成部分：1）增强癌症研究的广度、深度和影响力；2）促进转化；临床或社区环境中的发现；3）设计和进行假设驱动的试验改善癌症患者或有癌症风险的患者的治疗结果；4) 促进项目内和项目间合作；和跨学科团队科学；5）增强 COE 以解决优先癌症和癌症问题在 SCC 学区盛行； 6) 增加学生的培训和指导机会；教师；以及 7) 提高 SCC 中代表性不足的少数群体和妇女的比例领导和成员资格，以及管道项目的监督、规划和评估。 SCC 主任 Robert Mannel 医学博士组建了一支经验丰富的高级领导团队副主任 (AD) 负责监督以下职能：基础研究（Danny Dhanasekaran 博士）；转化研究（Priyabrata Mukherjee，博士）；临床研究（Kathleen Moore，医学博士）；外展和参与（MarkDoscher，医学博士）；教育、培训和职业提升（Rajagopal） Ramesh，博士）；多样性、公平性和包容性（Joan Walker，医学博士）和研究管理（Wade）；威廉姆斯博士）。自 2006 年 Mannel 被任命为 SCC 主任以来，战略规划和评估一直发挥着核心作用。常设研究领导委员会 (RLC) 和研究在 SCC 发展中的作用。指导委员会 (RSC) 由 SCC 所有研究部门的领导者组成，提供规划和评估进展的定期论坛此外，研究领导力也得到充分体现。 SCC 临床规划和评估。科学和社区咨询委员会的外部投入得到加强。这些规划和评估活动是在规划讨论期间出现的。报告期包括：研究计划调整（2018年）；老年科学中心（2018 年）和哈罗德·哈姆糖尿病中心（2019 年）；加强 SCC 的新举措；重点关注流域重点癌症和普遍癌症问题的研究有所增加（2019 年）；与诺曼大学合作，促进以癌症为重点的研究和合作（2020）； AD 的多样性、公平性和包容性立场，以及如何增强 SCC 之间的 DEI 的广泛规划领导力和会员资格，以及管道教育计划（2021 年）。